The Latest Cardiac and Vascular News
Aggregate Gross Proceeds of $143.7 Million from Public Offering and Private Placement THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock. The closing included the issuance and sale of an […]
THE WOODLANDS, Texas, June 01, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering […]
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study Conference Call and Webcast […]
NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones. “Our NDA for […]
Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) […]
NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, March 02, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, […]
NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic Neuropathy to Be Presented at 16th Annual Pain Therapeutics Summit Next Week Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Nov. 09, 2022 (GLOBE NEWSWIRE) — Lexicon […]
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30 and 90 Days Following Hospital Discharge THE WOODLANDS, Texas, Nov. 06, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study […]
Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies Recent Publication in the Journal Diabetes Care Evaluates Metabolic, Intestinal and Cardiovascular Effects in a Clinical Study THE WOODLANDS, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that […]
Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) […]
